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Introduction: Serological surveillance (serosurveillance) provides the most direct measure 
of herd immunity of vaccine-preventable diseases. Little is known about the opportunities 
and challenges of serosurveillance experiences, particularly pertussis.
Objective: To describe the process of serosurveillance for vaccine-preventable diseases with 
an emphasis on the experience of pertussis in the metropolitan area of Antioquia (Valle de 
Aburrá) in 2015 and 2016 and analyze the contributions and challenges for its sustainability.
Materials and methods: We described the planning and conduction of serosurveillance 
of pertussis antibodies of mothers and in the umbilical cord at the time of delivery in eight 
hospitals based on random sampling and their capacity to advance the serosurveillance 
periodically. We compared the contributions and the challenges of this experience with 
other probabilistic and non-probabilistic programs.
Results: We achieved the participation of hospitals and mothers respecting the delivery 
care process. We established a serum bank following ethical and technical guidelines. 
This program based on the random selection of hospitals and mothers has enabled the 
estimation of antibodies prevalence in mothers and in the umbilical cord, which has been 
possible given the high coverage of hospital care during childbirth at a lower cost and fewer 
risks than a population-based survey in conflictive areas. The main challenges for the 
sustainability of this program are the creation of stable jobs and access to funding and legal 
and methodological long-term frameworks.
Conclusions: Hospital serosurveillance as described is an option to monitor the impact of 
vaccination on the population. Our experience could be reproduced in other regions under 
similar conditions if the above-mentioned challenges are solved.
Keywords: Pertussis; seroepidemiological studies; immunization; antibodies; immunity, 
herd; Colombia.
Serovigilancia de enfermedades prevenibles por vacunación: una mirada desde la 
experiencia con la tosferina 
Introducción. La vigilancia serológica es la forma más directa de medir la inmunidad 
de rebaño frente a las enfermedades prevenibles por vacunación. Poco se sabe acerca 
de las oportunidades y los desafíos de las experiencias de serovigilancia, en general y, 
específicamente, la de la tosferina.
Objetivo. Describir el proceso de serovigilancia de enfermedades prevenibles 
por vacunación con énfasis en la experiencia en el caso de la tosferina en el área 
metropolitana de Antioquia (Valle de Aburrá) en el 2015 y el 2016 y analizar lo que dicha 
experiencia ha aportado y los desafíos que persisten para su sostenibilidad. 
Original article
doi: https://doi.org/10.7705/biomedica.v39i4.4181
Received: 08/02/18
Accepted: 31/01/19
Published: 06/02/19
Citation: 
Hincapié-Palacio D, Acevedo M, Hoyos 
MC, González C, Ochoa J, Pérez PA, et al. 
Serosurveillance for vaccine-preventable diseases: 
A look inside the pertussis experience. Biomédica. 
2019;39(Supl. 2):130-43.
https://doi.org/10.7705/biomedica.v39i4.4181
Corresponding author: 
Doracelly Hincapie-Palacio, Calle 62 N° 52-59, 
Medellín, Colombia
Telephone: (574) 219 6827; fax: (574) 219 6830
doracelly.hincapie@udea.edu.co
Author contributions: 
Doracelly Hincapié-Palacio, Marcela Acevedo, Maria 
Cristina Hoyos and Jesús Ochoa: Study conception 
and design
Doracelly Hincapié Palacio and Marcela Acevedo: 
Drafting of the manuscript
All authors participated in the collection and 
interpretation of the data and in the critical revision.
Funding:
Ministerio de Salud y Protección Social and 
Universidad de Antioquia, Agreements 313/ 2015 
and 448/2016
Conflicts of interest:
The authors declare no conflicts of interest. The 
Ministerio de Salud y Protección Social of Colombia 
participated in the discussion of the pertussis study 
design and in the review of this manuscript, which did 
not influence the analysis or the decision to publish 
the study results.
Salud Pública “Héctor Abad Gómez”, Universidad de Antioquia, Medellín, Colombia
Medellín, Colombia
Medellín, Medellín, Colombia
Colombia
Salud y Protección Social, Bogotá, Colombia
131
Biomédica 2019;39(Supl.2):130-43 Serosurveillance from the pertussis experience
Materiales y métodos. Se describió el proceso de planeación y el desarrollo de la 
serovigilancia de tosferina en el momento del parto en ocho hospitales seleccionados 
al azar, así como la capacidad para adelantar el programa de manera periódica. Se 
compararon los aportes y los desafíos en el curso de esta experiencia con los de otros 
programas poblacionales probabilistas e institucionales no probabilistas. 
Resultados. Se logró la participación de los hospitales y de las madres con pleno respeto 
del proceso de atención del parto, y se conformó un banco de sueros siguiendo lineamientos 
éticos y técnicos. El programa permitió estimar la prevalencia de anticuerpos en la madre 
y en el cordón umbilical, lo que se facilitó por la alta cobertura de atención hospitalaria 
del parto, a un menor costo y menos riesgos que los programas poblacionales en zonas 
conflictivas. Los principales desafíos para la sostenibilidad del programa son la estabilidad 
laboral del personal de salud, así como normas y una financiación de largo plazo.
Conclusiones. La serovigilancia hospitalaria es una opción para monitorizar el impacto 
poblacional de la vacunación. Esta experiencia se podría extender a otras regiones en 
condiciones similares si se resuelven los retos mencionados.
Palabras clave: tos ferina; estudios seroepidemiológicos; inmunización; anticuerpos; 
inmunidad colectiva; Colombia.
Serosurveillance is a strategy of epidemiology that seeks to monitor the 
dynamics of disease transmission using serological tests that establish the 
interrelation of the prevalence or incidence of infection and the behavior of 
susceptibility or immunity in population groups (1). This can help to determine 
the level of antibodies required to achieve herd immunity, to identify groups of 
susceptible individuals, to evaluate the persistence and duration of protective 
antibodies, to determine the effectiveness of vaccination, to document the 
elimination of diseases, and to define the need to modify the primary schemes 
including reinforcements or modifying the frequency of their application (1-3).
Serosurveillance was promoted in the 1960s by the World Health 
Organization (WHO) by establishing three reference serum banks based on 
the experience of seroepidemiological studies conducted since the 1930s and 
later promoted in the post-war period (4-7). These programs have been part 
of the vaccination programs; however, due to the reemergence of diseases, 
the conformation of a global serological bank has recently been proposed (8).
The data used to monitor the elimination and control of diseases come 
from epidemiological surveillance and vaccination coverage, which can 
be limited by inaccuracies in the population estimation, low vaccination 
effectiveness, reduced duration of protection, changes in the sensitivity and 
specificity of surveillance over time, and presence of subclinical or subnotified 
cases, among other (9).
The strategies used by serosurveillance are the determination of antibodies 
with samples for convenience from residual sera available in laboratories or the 
use of probabilistic population samples through seroprevalence surveys (10). 
In the present study, we analyzed the experience with pertussis 
serosurveillance using a probabilistic hospital approach in the metropolitan 
area (Valle de Aburrá) of Antioquia, identifying the capabilities, opportunities, 
and challenges for advances in the periodic and systematic use of this 
approach, and reviewing several publications on the subject.
In Colombia, pertussis vaccination began in 1980 with the DPT vaccine 
(diphtheria, pertussis, and tetanus) using a three-dose schedule (2, 4, and 6 
months) and two vaccine boosters (18 months and 5 years). Subsequently, 
with the resurgence of the disease between 2010 and 2012, vaccination of 
pregnant women with the acellular vaccine began in 2013 in Antioquia and 
Bogotá, which was later extended to the whole country (11).
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In Antioquia, the second most populated department of Colombia with more 
than 7 million inhabitants, we conducted a serosurveillance program in the 
metropolitan area (Valle de Aburrá) between 2015 and 2016, which estimated 
the prevalence of IgG PT antibodies against pertussis in mothers and the 
umbilical cord as a measure of antibody transfer. Additionally, the health status 
of the children was monitored during the first six months of life (12).
The purpose of describing the serosurveillance experience was to facilitate 
the extension of this approach to other regions of Colombia and similar 
countries.
Materials and methods
We described the experience of planning and conducting pertussis 
serosurveillance in the metropolitan area of Antioquia (Valle de Aburrá) 
between 2015 and 2016 including the methodological aspects, ethics 
committee approval, disclosure, data collection and management, collection 
of blood samples, and custody and conservation of information. The results of 
the pertussis seroprevalence study are shown in another publication (12).
The capabilities to consolidate a serosurveillance program in eight randomly-
selected hospitals and the Public Health Laboratory of Antioquia were analyzed 
after collecting the information with a structured interview. A questionnaire 
was designed to be answered by those in charge of clinical and public health 
laboratories. It included the following variables: Availability of locative and 
technological resources for the reception, processing, and conservation of blood 
samples; availability of hospital beds for delivery and postpartum care; previous 
experiences in serosurveillance and processing of samples from vaccine-
preventable diseases, and the identification of opportunities and challenges related 
to the implementation of serosurveillance as a regular and systematic program.
We also analyzed the contributions and challenges regarding the 
orientation of vaccination and epidemiological surveillance of hospital-based 
serosurveillance in light of other published experiences of probabilistic and 
non-probabilistic serosurveillance programs.
Results
Description of the procedures for hospital serosurveillance
The target population for the survey included mothers who came to 
the hospital for labor, were 37 weeks or more of gestation and agreed to 
participate in the study. We did not include mothers of multiple gestations, 
with fever in the previous 72 hours (chorioamnionitis and sepsis), treated at 
the intensive care unit, and in the advanced stage of labor. 
The study sample was made up of vaccinated and unvaccinated mothers 
against acellular pertussis during pregnancy (n=1,000). The size estimation of 
the sample was made according to the data of antibodies averages of vaccinated 
and unvaccinated pregnant women and their range or standard deviation 
according to reports from previous studies (minimum value of 2, maximum of 
360, variance of 7,569 to 8,010, 95% confidence, and 80% potency) (13-15). 
The sample size was 500 vaccinated mothers and 500 unvaccinated mothers. 
However, due to the difficulty of recruiting unvaccinated mothers during the 
study period (two years after starting the vaccination of pregnant women against 
pertussis), unvaccinated mothers had to be recruited before vaccination and at 
the time of delivery in two of the randomly-selected hospitals.
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The sampling was multi-stage and stratified by municipalities and by 
hospital conglomerates. The primary sampling units were hospitals in the 
municipalities of Valle de Aburrá. The secondary sampling units were all the 
mothers who came to hospitals for delivery care and met the inclusion criteria. 
The affixation of the sample was proportional to the childbirths attended within 
each hospital in the municipality.
One municipality had to be excluded because the public hospital chosen 
randomly had to suspend the childbirth service due to financial deficits. 
Furthermore, two selected private hospitals could not participate because the 
childbirth services were in the process of closing down.
For the random selection of hospitals, we considered the number of deliveries 
in 17 urban hospitals of the metropolitan area of Antioquia (Valle de Aburrá) and 
the data from nine municipalities of this sub-region including: Tdap vaccination 
coverage among pregnant women, incidence of pertussis, and distribution of the 
population according to the type of affiliation to the health social security system.
After signing the informed consent, mothers were surveyed on basic 
aspects including sociodemographic factors, antecedents of pregnancy, 
childbirth, vaccination, and disease. Other information sources were the daily 
delivery books (manual or electronic depending on availability), the national 
electronic registry of the expanded program of immunizations (PAIWeb), and 
hospitals’ medical records.
We prepared a procedure manual including a detailed description of 
participants selection and the procedure for obtaining informed consents; 
technical procedures for the randomization and identification of participants; 
data collection and completion of the survey; sample handling procedure and 
construction of the serum bank; follow-up of the newborn and the procedures 
related to the handling of the data, the analysis plan, and the mathematical 
modeling of prevention and control options. 
The proposal was endorsed by the Ethics Committee of the Facultad 
Nacional de Salud Pública “Héctor Abad Gómez” of the Universidad de 
Antioquia (session 129-15 Oct., 2015) and the ethics or research committees 
of the health institutions selected. 
We sought the support of the directorates or medical councils, the personnel 
in charge of epidemiological surveillance, the hospitals’ infection control units, 
the immunization programs, and the quality control and occupational health 
units. The number of birthing beds, delivery rooms, and postpartum beds varied 
according to the public or private nature of the health institutions (table 1).
All health institutions had data from mothers on manual or electronic 
medical records. The characteristics of the information systems, the clinical 
history, and the equipment of specific areas are summarized in table 2.
Table 1. Characteristics of hospitals participating in the pertussis serosurveillance, Valle de 
Aburrá, 2015-2016
Number
Public Private
Total I1 I2 I3 Total I4 I5 I6 I7 I8
Birthing beds
Delivery care rooms
Postpartum beds
22
8
54
6
3
24
10
3
20
6
2
10
57
17
135
16
2
16
18
5
75
10
3
12
5
5
24
8
2
8
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Table 2. Capabilities for serosurveillance according to the participating health institutions
I1 I2 I3 I4 I5 I6 I7 I8 I9
Serum bank available No No No No, only 
serum storage 
for 15 days
No, only serum 
storage for 15 
days
No, only 
serum storage 
for 30 days
No No, only 
serum storage 
for 30 days
Yes
Blood bank program Yes No No No Yes No Yes No Yes
Own laboratory 
headquarters
Yes Yes No No No No Yes Yes No
Processing samples 
with own resources
Yes Yes Yes Yes Yes Yes No Yes Yes
Hiring with another 
laboratory for the 
processing of samples
Yes Yes No Yes No Yes No Yes No
Analysis of samples 
for vaccine-
preventable diseases
Hepatitis 
B and C 
Rubella
Rapid 
test for 
hepatitis B
Rubella, 
but sending 
it to the 
reference 
laboratory 
Hepatitis B 
and C
Rubella and 
chickenpox
Hepatitis 
B and C 
Hepatitis D 
Rubella and 
chickenpox
Hepatitis B, 
hepatitis C, 
hepatitis D
Rubella, 
chickenpox and 
measles
Hemophylus 
influenzae B 
Neisseria 
meningitidis A 
Neisseria 
meningitidis B 
Neisseria 
meningitidis C 
Streptococcus 
pneumoniae in 
LCR
Bordetella 
pertussis 
Tuberculosis
Hepatitis B 
chickenpox
Hepatitis B
Hepatitis A
Rubella, 
chickenpox, 
measles and 
rotavirus
Bordetella
Tuberculosis
Hepatitis B 
and C
Rubella, 
chickenpox 
and 
tuberculosis
Hepatitis A 
and B
Rubella, 
chickenpox, 
measles and 
tuberculosis
Meningitis
Mumps
Hiring for the 
processing of 
samples of vaccine-
preventable diseases
Yes, rubella Yes, 
measles 
mumps
Yes,  
pertussis
Measles 
Mumps 
Pertussis
No Yes, rubella 
Pertussis
No Yes, measles 
Mumps 
Pertussis
No
Availability of laminar 
flow cabin/biological 
safety cabin
Yes, simple Yes, simple Yes, simple Yes Yes No Yes Yes Yes
Air-conditioned 
locations
Yes Yes Yes, partially Yes Yes Yes Yes Yes Yes
Refrigerators 
available for 
specimen storage 
between 2 and 8 °C 
with temperature 
sensor and calibration 
plate (number of)
Yes: 2 Yes: 2 Yes: 1 Yes: 5 Yes: 1 cold 
room
Yes: 2 Yes, 1 
cooling 
cellar
Yes, 1 cooling 
cellar
Yes: 8
Availability of 
refrigerators for 
reagent storage 
between 2 and 8 °C 
with temperature 
sensor and calibration 
plate (amount)
Yes: 5 Yes: 2 Yes: 2 Yes: 8 Yes: 2 Yes: 1 Yes: 3 Yes: 2 Yes: 6 
Availability of freezer 
at -20 °C with 
temperature sensor 
and with calibration 
plate (number of)
Yes, 
1 for 
reagents
1 for samples
Yes, 3 
freezers
Yes, 2 
freezers
Yes, 1 cold 
room 
1 freezer
Yes, 1 freezer 
cellar
Yes,1 freezer 
serum bank
Yes, 1 
cold room
Yes, 1 
cold room
Yes, 
3 freezers
Availability of 
software and / or 
alarm systems 
for temperature 
monitoring
Yes, 
systematized 
control with 
alarm: UBI 2
No, manual 
monitoring 2 
times a day
No, manual 
monitoring 2 
times a day 
with digital 
thermometer
Yes, satellite 
control with 
audible alarms 
and cell phone
Yes, but it is 
also verified 
manually.
No, manual 
record of the 
temperature, 
refrigerators 
with display for 
control
The software 
is pending for 
implementation.
No, 
reading the 
temperature 
on the 
digital panel 
(display)
Yes, 
computerized 
control with 
software-
mediated 
alarm
No, manual 
monitoring 2 
times a day
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We took the samples for serosurveillance within the regular process 
of delivery care. We explored the procedures that were part of the route 
of inclusion and attention of mothers, as well as the technical laboratory 
procedures as explained by the health personnel (figure 1).
We checked on the physical space, required inputs, and technical personnel 
involved in all the stages of the clinical and laboratory processes. In this way, 
we minimized the interference in the procedures already established in these 
places, ensuring the fluidity and continuity of the serosurveillance program.
We disseminated the information on the disease, the vaccination, and the 
project using printed educational materials and a web page (www.epiteorica.
com) addressed to health personnel, family, and visits.
We provided information to the mothers only when they were willing to 
listen to it according to their progress in labor. After providing the information, 
we obtained the consent and assent of the underage mothers and we 
conducted a brief survey. It was not possible to obtain blood samples from 
the children due to ethical and cultural objections; for this reason, we only 
Recruitment of pregnant women at delivery
Data collection
Handling samples
Data management
Admission for
delivery care
Basic data survey
Entry of samples to the
department’s Laboratory
Registration of
samples in serum
bank format
Distribution of serum or
plasma in three aliquots
Quali-quantitative technical assembly
SERION ELISA classic Bordetella pertussis
Freezing at -25 °C, 
until analysis
Report and delivery of
sample results
Cross check of received samples
and shipping formats
Processing and
cleaning of data
Creation and documentation 
of the database Individual report of results
Data analysis -
mathematical modeling -
dissemination of findings
Cross-checking of results database and
results reporting software
Quality
control
Data custody
Marking cryovials
identification labels
Final marking of cryovials
Assignment of serum
bank key
Blood sampling
Conservation and
shipment of samples
Umbilical cord sampling
during delivery
Tube check and sample
registration
Immediate shipment of
samples to the laboratory
Centrifugation and
refrigeration between 
2 and 8 °C
Shipping of samples to
the department’s
laboratory
Blood sample taken from
mother at delivery room
Verification of
inclusion criteria
Invitation to
participate
Informed consent
signature
Obtention of basic
anonymous data
of non participants
Accept End
Yes
No
Figure 1. Process of collection and management of serosurveillance data 
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carried out the clinical monitoring of the occurrence of pertussis during the 
first six months of age of the babies. The consent included the endorsement 
of later use of the sera collected for future investigations related to vaccine-
preventable diseases. Besides, we obtained basic information from non-
participating mothers.
The reagents to process the samples were selected taking into account 
the highest sensitivity and specificity reported in the literature (16). To ensure 
traceability of samples in all processes after they entered the laboratory, data 
were recorded in terms of collection, centrifugation, temperature and cooling 
time, transport, fractionation, and final inclusion in the serum bank. In each 
specimen, a code was assigned according to its type (G if it was from the 
mother and C if it was a cord), fraction number (F1, F2, F3 or FU if the sample 
was a single fraction), position in the cryobox (from A1 to J10), and date of 
entry to the serum bank. 
Databases on the handling of samples from the serum bank, data on 
laboratory results (antibodies from the mother and the umbilical cord), and 
the survey of mothers and children followed for six months were created and 
combined as necessary. The results of the laboratory and the interpretation of 
their meaning were sent to each mother through a letter delivered by regular 
mail or with the support of the vaccination service staff in some cases. We 
defined the databases documentation, analysis, and custody procedures 
omitting personal identification information.
The analysis took into account: a) The inference of the results of the 
sample to the population by estimating the inverse probability of being 
chosen and the weighing of variability at each stage of random sampling. This 
allowed us to estimate the confidence interval of proportions and weighted 
averages; b) the estimation of the trans-placental transport ratio as that of 
umbilical cord blood to maternal antibodies, and c) the mathematical modeling 
of disease-transmission dynamics by formulating a system based on 
differential equations of the relevant states and parameters and the deduction 
of the reproductive number that allows for estimating the critical proportion of 
immunity to achieve control, herd immunity or disease elimination.
We systematized the data in Access™ (Microsoft) databases while 
surveys and consents were digitized for 15-year-period conservation.
In the survey regarding the capacity of the institutions to implement 
a serosurveillance program, we observed that none of them had any 
program. All participating laboratories had an area for sample reception and 
fractionation and processing with adequate lighting and ventilation, as well 
as areas for the conservation of samples and reagents for both refrigeration 
and freezing under controlled temperature conditions. All had air conditioning, 
except Institution 3, which had partial flow (table 2).
Only the department’s Public Health Laboratory had ultra-freezers at -70 
°C with sensor and/or temperature monitoring using a system or specific 
software. However, the installed capacity of its three freezers was nearly 
100% occupied. 
All laboratories met the requirement of regular preventive maintenance 
of refrigerators and freezers with calibration support. They also had a power 
regulator system (supply plant) to support electrical faults or interruption in the 
light current.
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The participating institutions agreed on the aspects necessary for the 
implementation and strengthening of a serosurveillance program, such as 
training in the subject, centralization of the program in a reference entity, and 
dissemination of information highlighting the usefulness and importance of 
the program for evaluating the impact of vaccination and the epidemiological 
characterization of public health events. They also mentioned the need to have 
regulations to support custody, sample handling, and accreditation systems, as 
well as the provision of equipment and suitable assets to give solid support to 
the program and carry out cost-benefit analyses. All of them expressed interest 
in participating in the serosurveillance program. The main challenges identified 
were funding to ensure program sustainability and health personnel under 
indefinite-term contracts with sufficient time for program activities.
Experiences of probabilistic population serosurveillance
México, the Netherlands, and the United States have documented the 
contribution of serosurveillance based on random population studies (table 3). In 
1987, México conducted a national seroepidemiological survey and implemented 
a national serum bank, although it had advanced pertussis seroprevalence 
studies since the 1960s (17,18). In 1995 and 1996, the Netherlands conducted a 
study to evaluate the national serosurveillance immunization program including 
the creation of the national serum bank; the study was subsequently replicated 
in 2006 and 2007 (19,20). In the United States, the National Health and Nutrition 
Survey (NHANES) conducted a serological study on antibodies against certain 
vaccine-preventable diseases in the 1960s and an annual program since 1999. 
This program received legal approval for data collection and management (The 
Public Health Service Act 42 USC 242k) (21-25).
Based on these experiences, a population seroprevalence study 
was conducted in 2009 in Medellín, which estimated the prevalence of 
antibodies in the population (26-30) and obtained detailed information on 
the history of vaccination and the biological and social factors that could 
influence the presence of antibodies and guide vaccination policies based 
on the evidence of local epidemiology, as well as the use of mathematical 
modeling to estimate the critical proportion of immunity and the basic and 
effective reproductive number indicating the level of achievement of disease 
elimination (27,31). The percentage of participation in this population-based 
seroprevalence study was 88,5% (26) during a time of armed conflict in the 
city, which implied high costs, greater efforts and additional time.
Experience with non-probabilistic institutional serosurveillance
In 1986 and 1987, England and Wales implemented a convenience 
sampling to obtain sera to monitor changes in the prevalence of antibodies 
before and after the measles vaccination program (table 3) (5). In the 1990s, 
Australia considered serosurveillance as an important component of its 
surveillance system for vaccine-preventable diseases and in that same year, 
serum samples were compiled from associated laboratories to evaluate 
measles vaccination strategies (32,33) (table 3). 
In Europe, a serosurveillance network was formed in 1996 with the initial 
participation of six countries to standardize serological methods, which was 
started in some cases from residual samples available in laboratories and 
in others, from population studies (34) (table 3). A typical case was measles 
serosurveillance with samples obtained from the 1996-2000 and 2001-2003 
periods in 18 countries in order to identify susceptible cohorts and adjust 
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Table 3. Studies on serosurveillance experiences according to the approach used (random or not sampling)
Approach
Population / 
References
Origin Vaccination orientation Guidance of surveillance Challenges
Random 
population
United 
States (21) 
(22) (23) 
(24) (25)
NHANES began 
in the 1960s. 
Since 1999 it 
has been carried 
out annually.
It provides evidence for 
the evaluation of the 
impact of vaccination 
against human 
papillomavirus, analyzing 
seropositivity in the pre-
vaccination period and 
the association of annual 
seropositivity (subtypes 
6, 11, 16, and 18), and 
the self-reported history 
of cancer from 2003 to 
2010.
It allows estimation of the 
change of seroprevalence 
(2003-2010), the impact 
on public health and cost 
effectiveness of vaccination 
against hepatitis A from 
2006 to 2106, using data on 
seroprevalence, notification 
data, and a model of the 
dynamics of the transmission.
Opportunity is required in the detection and 
communication of clinically relevant findings.
Be alert to changes in methods or data 
management. This is updated in the 
documentation available on the internet.
Some variables are only available through 
the Research Center due to confidentiality 
considerations.
It is necessary to improve the comparability of 
the tests and analytical methods.
The results are generalized to non-
institutionalized individuals.
Mexico 
(17) (18)
They established 
a system of 
National Health 
Surveys in 
1985 (General 
Directorate of 
Epidemiology, 
National Institute 
of Statistics, 
Geography and 
Informatics, state 
governments).
The need to reinforce 
vaccination against 
measles was 
detected according 
to the distribution of 
susceptibility in children 
from 1 to 9 years old.
The low seroprevalence 
of antibodies against 
poliomyelitis in children 
younger than 10 years in 
the southern region of the 
country allowed to identify 
the need to strengthen 
surveillance and vaccination 
in this location.
Serological pertussis surveys were performed 
with difficulty in the comparison due to 
differences in the sample design, geographic 
extension, and number of samples (1965, 
1966, 1973, and 1987-1990).
Optimal use of collected samples 
(hemolysis, low volume, identification data 
not available)
Simultaneous realization of 18 projects on 
sample processing.
External control of the quality of the 
sample processing
Verification of contamination-free samples 
with sterility tests
Technical limitations in processing and 
analysis: Storage and processing capacity, 
availability of reagents, persistence of 
antibodies and opportunity for processing, 
cross-reactions, and storage conditions of 
samples and reagents
Netherlands 
(19) (20)
They formed 
a serum bank 
from cross-
cutting studies in 
1995/1996 and 
2006/2007.
Analysis of additional 
strategies in sampled 
populations: Immigrants 
and communities that 
reject vaccination for 
religious reasons.
Available data on 
vaccination and 
associated factors
Additional data on 
mathematical modeling of 
social contacts, genetics of 
the immune response and 
detection of food allergies 
and vaccines
Expensive though efficient for studying a 
broad spectrum of diseases
The response rate in the second survey 
was lower than in the first (55 vs. 33%); 
they have non-response data to analyze 
possible bias.
Participation of the public health service 
recognized at the local level
Support of clinics and regional administrators 
to access population records
Medellín, 
Colombia 
(26-28, 30)
A 
serosurveillance 
initiative was 
conducted 
based on a 
seroprevalence 
study in 2009 
providing 
documentation 
of the elimination 
of rubella and 
during a mumps 
epidemic.
The effect of 
vaccination against 
hepatitis B was 
evidenced by 
determining the 
increase of immunity 
vaccination in a birth 
cohort fifteen years 
after the beginning of 
the mass vaccination, 
the need to complete 
the vaccination 
scheme, and the factors 
potentially associated 
with the presence of 
immunity (natural and 
by vaccine).
Estimated population immunity 
to achieve the elimination of 
rubella in men and women 
from 6 to 64 years of age 
residing in urban and rural 
areas through mathematical 
modeling of the proportion of 
susceptible individuals by age 
at the time of documentation of 
the degree of progress in the 
elimination of the disease
The proportion of 
seronegativity and factors 
that could influence the 
occurrence of outbreaks of 
mumps were identified in an 
epidemic season.
Fieldwork was conducted in conditions of 
insecurity due to the resurgence of violence. 
With the support of community leaders, 
participation exceeded 85%.
The limitations in the funding of reagents did 
not allow for simultaneous processing of the 
available vials. The freezing-thawing of the 
vials was avoided.
The analysis of the recommendations to 
be given to each seronegative individual 
for rubella and parotiditis and individuals 
with chronic hepatitis was required before 
the ethical commitment of explanation and 
delivery of laboratory results. The Ministry 
of Health supported the vaccination 
activities and epidemiological surveillance 
of these individuals.
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Residual 
samples
England 
and Wales 
(5)
The first 
serological 
survey was 
conducted 
before the 
beginning 
of measles, 
mumps, and 
rubella (MMR) 
vaccination in 
1988.
Addition of the second 
dose of MMR in 
1996; suggested 
vaccination campaign 
in adults against MR; 
documented decision 
not to implement 
universal vaccination 
against hepatitis B, 
and introduced booster 
doses against diphtheria 
and tetanus in 1994.
Construction of a stock 
of sera to analyze 
other diseases (rubella, 
parotiditis, chickenpox, 
hepatitis A, parvovirus 
B19, Norwalk virus, etc.).
Evaluation of the effect 
of the initial scheme and 
vaccination campaigns 
against measles
Use of mathematical models 
to predict the occurrence of a 
measles epidemic
Complementary data on the 
incidence of hepatitis B
Rapid detection of the 
diphtheria emergency after 
the epidemic in the former 
USSR
Control of over-representation of women 
by prenatal care in the random selection 
of residual serum. No data were available 
on the ethnic group or country of birth. The 
selection bias was reduced because the 
health system has free access. Reduction of 
costs and discomfort in obtaining samples
Australia  
(32) (33)
The first survey 
was conducted in 
1999 to evaluate 
the effect of 
the measles 
vaccination 
campaign before 
and after its 
implementation in 
1998.
A cohort of young adults 
susceptible to measles 
was identified and a 
campaign of MMR was 
conducted in 2001.
In initial surveys, no 
impact on the immunity 
of measles, mumps, 
diphtheria, and tetanus 
was observed, but 
they recommended 
innovative and 
additional strategies in 
varicella and whooping 
cough.
Understanding of epidemiology 
from mathematical modeling 
of varicella transmission 
parameters and estimation of 
the probability of occurrence of 
measles epidemics
Need to strengthen 
surveillance in the case of a 
change of inactivated polio 
vaccine
Identification of some risk of 
hepatitis B in the northern 
region and natives of Asia
It may be more difficult to identify and control 
potential biases because the characteristics 
of participants and non-participants are 
unknown.
They tried to reduce the selection bias 
capturing samples from outpatients rather 
than hospitalized patients.
They obtained samples selected randomly 
by age group rather than by state or 
territory.
They observed similar results from random 
population sampling and residual samples 
except for diseases with oversampling due 
to increased uptake by diagnosis (e.g., 
hepatitis C).
The cost of collecting and preserving 
samples for each test in random sampling 
was about seven times more expensive 
than the equivalent in samples for 
convenience.
A decrease in the participation of 
laboratories in subsequent surveys by 
fusion or disappearance of laboratories, 
limitations of time availability, financing, 
and change of priorities
vaccination strategies accordingly. Also, these data were compared with the 
incidence reported in the surveillance and vaccination coverage. The analysis 
revealed that seven countries had a high susceptibility prevalence and low 
vaccination coverage, which led to the outbreaks in some of these countries (35).
Discussion
The uses of serosurveillance have been widely analyzed in the literature 
in terms of their contributions to vaccination and epidemiological surveillance 
programs and it is considered the most reliable strategy to monitor the 
population impact of vaccination (8,9).
The advantages and disadvantages of population and institutional 
serosurveillance approaches have been analyzed extensively (10,33).
In this study, we used a hospital approach, which had the advantage of 
obtaining estimates of the seroprevalence from the mother and the umbilical 
cord during labor and from probabilistic samples whose data can be inferred 
from the target population.
NHANES: National Health and Nutrition Examination Survey
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In our experience, the percentage of participation in population-based 
seroprevalence studies was high despite the resurgence of the armed 
conflict, which made household surveys risky. Providing detailed information 
on the usefulness of the study through different means such as household 
surveys, the use of newsletters, and telephone calls fostered participation. 
The participation of pregnant women in the determination of antibodies 
against pertussis at the time of delivery and the follow-up of the newborn was 
achieved using "active" recruitment strategies (36), such as the involvement 
of the family and the health personnel, showing respect for the process 
of childbirth care, the willingness of hospitals to participate, the support of 
the health secretaries, and the documentation of the research experience 
undertaken by the university team in charge of the project through different 
means (web page and others).
We also reviewed experiences of non-probabilistic institutional 
serosurveillance generally based on residual samples available in laboratories 
or blood banks from health services users. This approach requires less 
time, effort and investment than the population approach but it has limited 
possibilities of population inferences given its convenience sampling.
This study reported on the experience of a hospital serosurveillance 
approach during 2015 and 2016 based on the combination of the institutional 
approach and random selection of participating hospitals. This approach had 
the advantage of optimal handling of the samples in the hospitals’ laboratories 
and their subsequent transfer to a public health laboratory for processing. In 
addition, the risks of health personnel in charge of collecting the data areas 
affected by armed confrontations were reduced, as well as the costs and 
the time required for fieldwork. The existence of hospital admission records 
allowed for the analysis of differences between participating and non-
participating mothers to identify and control a potential selection bias (12). The 
mathematical modeling constructed in local seroprevalence studies allowed 
to take advantage of the data collected in their course and in epidemiological 
surveillance for identifying disease control and elimination options (27,37).
However, several challenges remain and should be faced to advance in 
this type of initiatives. First, it is necessary to have a regulatory framework 
to support serosurveillance as a complement to epidemiological surveillance 
of vaccine-preventable diseases. Second, the hiring of indefinite term health 
personnel is required to ensure the sustainability of the serosurveillance 
program and the continuity of the activities at all levels. Third, training on the 
usefulness of serosurveillance and the construction of strategies for resolving 
difficulties is also required.
These challenges relate to the organization of health services provision. 
During the serosurveillance, we observed how some obstetric and 
gynecological services shut down or were reduced, as well as financial 
deficits which affected the quality of childbirth-related attention. 
Hospital serosurveillance can be affected by health services coverage. 
Nevertheless, the coverage of hospital care during childbirth has increased 
(38), which may reduce this limitation. Other sources of information on hospital 
serosurveillance, such as blood banks, allowed us to estimate only the 
prevalence of diseases associated to the risk of transmission via transfusion 
and depend on the access to and the acceptance of health services. The 
sampling at the time of delivery is preferable to collect residuals derived from 
prenatal control such as umbilical cord samples, which is a practice allowed.
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Ethical considerations restricted the collection of umbilical cord samples 
from the children, but they were monitored during the first six months of life 
for pertussis (12). Due to budgetary restrictions, we processed only pertussis 
antibodies, although three vials of serum were available. Other studies have 
analyzed the transfer of multiple diseases antibodies, such as diphtheria, 
tetanus, and meningitis (19,39), as well as the utility of influenza (40) and 
chickenpox (41) serosurveillance.
This study aimed at the identification of serosurveillance capacity in 
the participating institutions and the creation of a serum bank, as currently 
there are around 5,000 specimens available for further analysis, which is 
close to the adequate number required for monitoring population immunity 
in other countries (19) and responded to the current tendency of studying 
antibodies transfer from the mother to the umbilical cord or the newborn as 
recommended in mass immunization or epidemics management strategies, 
especially when seroprevalence or serosurveillance programs exist (42,43). 
This paper described the serosurveillance activities carried out in 2015 
and 2016 in the participating institutions, but given that epidemiological and 
vaccination strategies vary with time, they should be repeated in five or ten 
years to monitor changes in population immunity against diseases associated 
with transplacental transfer of antibodies (20). 
Serosurveillance can guide vaccination and prevent the occurrence of 
epidemics and the resurgence of diseases at local and global levels (8). 
The experience documented in this work regarding hospital serosurveillance 
programs could be replicated in other places under similar conditions as an 
opportunity to strengthen public health laboratories and integrate vaccination 
and surveillance programs of vaccine-preventable diseases.
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